Purpose: This study evaluates the anti-tumor effect of regional chemotherapy compared with chemoembolization in an animal model.
Materials And Methods: Twenty-one rabbits bearing VX2 liver tumors were divided into the following four groups: (a) the transarterial (TA) group (n=6) received a transarterial injection of doxorubicin through the hepatic artery (1 mg/kg); (b) the transarterial and transportal (TAP) group (n=6) received injections of doxorubicin through both the hepatic artery (1 mg/kg) and the portal vein (1 mg/kg); (c) the transarterial chemoembolization (TACE) group (n=6) received a transarterial injection of doxorubicin (1 mg/kg) followed by gelatin sponge embolization; and (d) the control group (n=3) received no treatment. With the use of computed tomography, tumor growth rates were calculated and microscopic examinations were performed to evaluate the extent of tumor necrosis.
Results: Seven days after each treatment, the mean tumor growth rates were 216.7%±189.0% in the TA group, 77.1%±73.9% in the TAP group, and 489.5%±352.1% in the control group; there were no significant differences in tumor growth rates (P = 0.057). The tumor growth rate of the TACE group could not be evaluated due to extensive liver necrosis. The mean tumor necrosis rates were 41.9%±11.5% in the TA group, 51.4%±11.1% in the TAP group, 94.7%±3.5% in the TACE group, and 29.3%±6.7% in the control group; the TACE group showed significantly higher tumor necrosis than any other groups.
Conclusion: Single session regional chemotherapy has limited anti-tumor effects when compared with TACE in the rabbit VX2 tumor model.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4261/1305-3825.DIR.4016-10.1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Survival of patients with non-viral hepatocellular carcinoma treated with trans-arterial chemoembolization: A multicenter cohort study.
Arab J Gastroenterol
January 2025
Hepatology and Gastroenterology Department, National Liver Institute, Menoufia University, Menoufia, Egypt.
Background And Study Aims: Few studies have considered patients treated with trans-arterial chemoembolization (TACE) for non-viral-induced hepatocellular carcinoma (HCC), with some reporting that those patients may have larger tumors, emphasizing the need for determination of the factors affecting survival in such patients. This work aims to study the characteristics and survival of patients with non-viral related HCC treated with TACE.
Patients And Methods: This is a multicenter observational study.
Gemcitabine-Loaded Microbeads for Transarterial Chemoembolization of Rabbit Renal Tumor Monitored by F-FDG Positron Emission Tomography/X-Ray Computed Tomography Imaging.
Pharmaceutics
December 2024
Department of Urology and Department of Nuclear Medicine, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai 201399, China.
Background/objectives: The purpose of this study was to develop the gemcitabine-loaded drug-eluting beads (G-DEBs) for transarterial chemoembolization (TACE) in rabbit renal tumors and to evaluate their antitumor effect using 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography/X-ray computed tomography (F-FDG PET/CT).
Methods: DEBs were prepared by polyvinyl alcohol-based macromer crosslinked with -acryl tyrosine and ,'-methylenebis(acrylamide). Gemcitabine was loaded through ion change to obtain G-DEBs.
Surgical resection versus thermal ablation: comparison of sequential options after successful TACE downstaging therapy for unresectable hepatocellular carcinoma.
Ther Adv Med Oncol
January 2025
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Minimal Invasive Intervention, Sun Yat-sen University Cancer Center, 651, Dongfeng East Road, Guangzhou 510060, P.R. China.
Background: Transarterial chemoembolization (TACE) is an effective and safe downstaging therapy for hepatocellular carcinoma (HCC). However, the selection of sequential therapeutic modalities is still controversial.
Objectives: This study compared the effectiveness and safety of surgical resection (SR) and thermal ablation (TA) after patients with HCC underwent TACE downstaging therapy.
Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC: An international observational study.
JHEP Rep
January 2025
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China.
Background & Aims: Current prognostic models for patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE) are not extensively validated and widely accepted. We aimed to develop and validate a continuous model incorporating tumor burden and biology for individual survival prediction and risk stratification.
Methods: Overall, 4,377 treatment-naive candidates for whom TACE was recommended, from 39 centers in five countries, were enrolled and divided into training, internal validation, and two external validation datasets.
Background: This case series evaluated the clinical impact and significant technical points of transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) using the smaller drug-eluting bead (DEB) M1 (DC Bead M1; 70-150 µm).
Methods: We evaluated 12 patients and 14 HCC nodules treated with DEB-TACE using the DC Bead M1 (named DEM1-TACE). In addition to evaluating the early treatment efficacy for each treated node after DEM1-TACE, the study also used interventional radiology (IVR)- computed tomography (CT) to focus on the presence or absence of retention of the homogeneous contrast medium in target nodules after DEM1-TACE as a predictor of a good treatment response.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!